SPOTLIGHT: Hebrew University launches nanotech spinoff

Hebrew University of Jerusalem has spun off a start-up nanotech company with new technology for the release of lipophilic drugs. The university's tech transfer company, Yissum, created Nanolymf from new technology developed by Prof. Simon Benita at the Hebrew University's School of Pharmacy. "The ability to deliver lipophilic drugs orally while bypassing specific potent barriers in the intestine and the liver carries tremendous potential," says Nava Swersky Sofer, CEO of Yissum. "Professor Benita, a seasoned inventor and entrepreneur and the founder of Novagali SA, one of Yissum's most promising spin-offs, has once again demonstrated his ingenuity in developing a novel mechanism addressing many unmet medical needs." Release

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.